The DOI matches its Crossref record; 51 of the 54 references it cites were found in a registry or an index.
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Open accessPublished version of a preprint
Abstract
Poly(ADP-ribose) polymerase-1 (PARP-1) inhibition is toxic to cells with mutations in the breast and ovarian cancer susceptibility genes BRCA1 or BRCA2, a concept termed synthetic lethality. However, whether this approach is applicable to other human cancers with defects in other DNA repair genes has yet to be determined. The ataxia telangiectasia mutated (ATM) gene is altered in several human cancers including mantle cell lymphoma (MCL). Here, we characterize a panel of MCL cell lines for ATM status and function and investigate the potential for synthetic lethality in MCL in the presence of small-molecule inhibitors of PARP-1. We show that Granta-519 and UPN2 cells have low levels of ATM protein, are defective in DNA damage-induced ATM-dependent signaling, are radiation sensitive, and have cell cycle checkpoint defects: all characteristics of defective ATM function. Significantly, Granta-519 and UPN2 cells were more sensitive to PARP-1 inhibition than were the ATM-proficient MCL cell lines examined. Furthermore, the PARP-1 inhibitor olaparib (known previously as AZD2281/KU-0059436) significantly decreased tumor growth and increased overall survival in mice bearing s.c. xenografts of ATM-deficient Granta-519 cells while producing only a modest effect on overall survival of mice bearing xenografts of the ATM-proficient cell line, Z138. Thus, PARP inhibitors have therapeutic potential in the treatment of MCL, and the concept of synthetic lethality extends to human cancers with ATM alterations. Mol Cancer Ther; 9(2); 347–57
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Finally, depletion of suv39h1 increased cell sensitivity to PARPi (Fig. 6D), consistent with previous reports that cells lacking ATM are sensitive to PARP inhibition (34,35).”
From DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin (2014) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationDNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Amé, J., & de MURCIA, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,975
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311
Self-citationATM and DNA-PK Function Redundantly to Phosphorylate H2AX after Exposure to Ionizing Radiation
Stiff, T., O’Driscoll, M., Rief, N., Iwabuchi, K., Löbrich, M., & Jeggo, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3207 · Cited by 1,050
Cited by
Sorted by citations
Items 101–194 of 194
Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences
Carrassa, L., Colombo, I., Damia, G. L. M., & Bertoni, F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102090 · Cited by 29
Chen, H., Zeng, X., Gao, C., Ming, P., Zhang, J., Guo, C., Zhou, L., Lu, Y., Wang, L., Huang, L., et al. (2015) · Scientific Reports · doi:10.1038/srep10893 · Cited by 26
“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
Incorvaia, L., Passiglia, F., Rizzo, S., Galvano, A., Listì, A., Barraco, N., Maragliano, R., Calò, V., Natoli, C., Ciaccio, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14409 · Cited by 26
Changing the course of pancreatic cancer – Focus on recent translational advances
Javle, M. M., Golan, T., & Maitra, A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.004 · Cited by 24
Trial watch – inhibiting PARP enzymes for anticancer therapy
Sistigu, A., Manic, G., Obrist, F., & Vitale, I. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1053594 · Cited by 25
Genetic Variation in DNA Repair Pathways and Risk of Non-Hodgkin's Lymphoma
Rendleman, J., Antipin, Y., Reva, B. A., Adaniel, C., Przybylo, J. A., Dutra-Clarke, A. V. C., Hansen, N. A. L., Heguy, A., Huberman, K. H., Borsu, L. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101685 · Cited by 24
Tumor protein D52 represents a negative regulator of ATM protein levels
Chen, Y., Kamili, A., Hardy, J. R., Groblewski, G. E., Khanna, K. K., & Byrne, J. A. (2013) · Cell Cycle · doi:10.4161/cc.26146 · Cited by 23
Laurent, A., & Blasi, F. (2015) · Development · doi:10.1242/dev.125708 · Cited by 22
PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias
Fritz, C. E., Portwood, S. M., Przespolewski, A., & Wang, E. S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100696 · Cited by 23
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
Osoegawa, A., Gills, J. J., Kawabata, S., & Dennis, P. A. (2017) · Oncotarget · doi:10.18632/oncotarget.19667 · Cited by 21
PARP Inhibitors and Haematological Malignancies—Friend or Foe?
Skelding, K. A., & Lincz, L. F. (2021) · Cancers · doi:10.3390/cancers13215328 · Cited by 20
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
Liao, M., Beltman, J., Giordano, H., Harding, T. C., Maloney, L., Simmons, A. D., & Xiao, J. J. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01157-8 · Cited by 20
Principe, D. R., Narbutis, M., Koch, R. M., & Rana, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-76975-6 · Cited by 20
Jang, A., Sartor, O. A., Barata, P. C., & Paller, C. J. (2020) · Cancers · doi:10.3390/cancers12113467 · Cited by 20
Yang, Z., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., Zhang, J., & Xie, Y. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05124-5 · Cited by 20
Węsierska‐Gądek, J., & Składanowski, A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.175 · Cited by 17
Bhalla, K., Jaber, S. M., Reagan, K., Hamburg, A., Underwood, K. F., Jhajharia, A., Singh, M., Bhandary, B., Bhat, S., Nanaji, N. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78193-6 · Cited by 17
DNA damage pathways and B-cell lymphomagenesis
Knittel, G., Rehkämper, T., Nieper, P., Schmitt, A., Flümann, R., & Reinhardt, H. C. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000433 · Cited by 18
Golla, R. M., Li, M., Shen, Y., Ji, M. H., Yan, Y., Fu, K., Greiner, T. C., McKeithan, T. W., & Chan, W. C. (2011) · Hematological Oncology · doi:10.1002/hon.1020 · Cited by 17
Suh, K. J., Ryu, H. S., Lee, K.-H., Kim, H., Min, A., Kim, T., Yang, Y., Moon, H., Han, S., Oh, D., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3869-x · Cited by 17
Lee, S., Kim, J., Jeong, E., & Myung, K. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103887 · Cited by 16
Kivlin, C. M., Watson, K. L., Sannaa, G. A. A., Belousov, R., Ingram, D. R., Huang, K.-L., May, C. D., Bolshakov, S. V., Landers, S. M., Kalam, A. A., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1108486 · Cited by 16
Acceleration or Brakes: Which Is Rational for Cell Cycle-Targeting Neuroblastoma Therapy?
Ando, K., & Nakagawara, A. (2021) · Biomolecules · doi:10.3390/biom11050750 · Cited by 16
Absence of Wip1 partially rescues Atm deficiency phenotypes in mice
Darlington, Y. F., Nguyen, T.-A., Moon, S.-H., Herron, A., Rao, P., Zhu, C., Lu, X., & Donehower, L. A. (2011) · Oncogene · doi:10.1038/onc.2011.303 · Cited by 15
Yang, L., Yang, X., Tang, Y., Zhang, D., Zhu, L., Wang, S., Wang, B., & Ma, T. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8828 · Cited by 16
Nasuno, T., Mimaki, S., Okamoto, M., Esumi, H., & Tsuchihara, K. (2013) · Cancer Science · doi:10.1111/cas.12322 · Cited by 15
Ho, C. K., Kornaga, E. N., Klimowicz, A. C., Enwere, E. K., Dean, M. L., Bebb, G. D., Phan, T., Ghatage, P., Magliocco, A. M., Lees‐Miller, S. P., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.12.025 · Cited by 14
Self-citationJette, N., Radhamani, S., Ye, R., Yu, Y., Arthur, G., Goutam, S., Bismar, T. A., Kumar, M., Bose, P., Yip, S., et al. (2020) · Genome Instability & Disease · doi:10.1007/s42764-020-00011-0 · Cited by 14
Self-citationSelective tumor killing based on specific DNA-damage response deficiencies
Biss, M., & Xiao, W. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.18921 · Cited by 13
Muvaffak, A., & Coleman, K. G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1380633 · Cited by 12
Couto, C. A.-M., Hsu, D., Teo, R., Rakhimova, A., Lempidaki, S., Pears, C. J., & Lakin, N. D. (2013) · Journal of Cell Science · doi:10.1242/jcs.128769 · Cited by 12
Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer.
Chen, X., Chen, Z., Zheng, B., & Tang, W. (2019) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2018.11.062 · Cited by 13
Inhibition of ATM with KU-55933 Sensitizes Endometrial Cancer Cell Lines to Olaparib
Zhang, A., Zhang, L., Xie, X., & Liu, D. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s426923 · Cited by 11
Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism
Abugable, A. A., Awwad, D. A., Fleifel, D., Ali, M. M., El‐Khamisy, S. F., & Elserafy, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-60733-7_9 · Cited by 11
Miller, R. M., Nworu, C. U., McKee, L., Balcerzak, D., Pham, L., Pugh, J., Liu, Y., Gustafson, H. L., Marwah, E., Lamb, T., et al. (2019) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000786 · Cited by 11
Targeting the DNA damage response in hematological malignancies
Mel, S. D., Lee, A. R. Y. B., Tan, J. H. I., Tan, R., Poon, L. M., Chan, E. H. L., Lee, J., Chee, Y. L., Lakshminarasappa, S. R., Jaynes, P. W., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1307839 · Cited by 11
Exploiting the DNA Damage Response for Prostate Cancer Therapy
Stracker, T. H., Osagie, O. I., Escorcia, F. E., & Citrin, D. E. (2023) · Cancers · doi:10.3390/cancers16010083 · Cited by 12
Warrener, P., Kim, S., Williams, S. M. G., Biery, M. C., Gordon, M. L., Toniatti, C., Cleary, M. A., Linsley, P. S., & Carleton, M. O. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0707-4 · Cited by 10
Orlando, L., Schiavone, P., Fedele, P., Calvani, N., Nacci, A., Cinefra, M., D’amico, M., Mazzoni, E., Marino, A., Sponziello, F., et al. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648925 · Cited by 8
Radhakrishnan, S. K., Bebb, D. G., & Lees‐Miller, S. P. (2013) · Translational Cancer Research · doi:10.21037/1123 · Cited by 8
Self-citationOlson, D. J., Bhalla, S., Yang, X. J., Martone, B. K., & Kuzel, T. M. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.03.012 · Cited by 8
ATM inhibitors in cancer radiotherapy: Mechanisms, clinical development, and future directions
Al‐Zoubi, R. M., Garada, K., Huneidi, R. A., Baddar, Z. M. H., Zarour, A. A., Elaarag, M., Al-Zoubi, S. R., Al-Qudimat, A. R., Zoubi, M. S. A., Agouni, A., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118137 · Cited by 8
Curtis, A. D., Rueter, J., Rajan, S., Zhang, R., & Shopland, L. S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26773 · Cited by 7
A Phase I Trial of Talazoparib in Patients with Advanced Hematologic Malignancies
Gopal, A. K., Popat, R., Mattison, R. J., Menne, T., Bloor, A. J. C., Gaymes, T. J., Khwaja, A., Juckett, M., Chen, Y., Cotter, M. J., et al. (2021) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2021-0004 · Cited by 7
ATM and ATR gene editing mediated by CRISPR/Cas9 in Chinese Hamster cells
Maëda, J., Chailapakul, P., & Kato, T. A. (2024) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2024.111871 · Cited by 7
Verner, J., Trbušek, M., Chovancová, J., Jašková, Z., Moulis, M., Folber, F., Halouzka, R., Mayer, J., Pospı́šilová, Š., & Doubek, M. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1034701 · Cited by 6
Jalal, S. I., Dewalt, R. I., Kesler, K. A., Hammoud, Z. T., Baldridge, L., & Hattab, E. M. (2014) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s57594 · Cited by 6
Mantle cell lymphoma: insights into therapeutic targets at the preclinical level
Klener, P. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1813718 · Cited by 5
Everix, L., Nair, S., Driver, C. H. S., Goethals, I., Sathekge, M. M., Ebenhan, T., Vandevoorde, C., & Bolcaen, J. (2022) · Cancers · doi:10.3390/cancers14071821 · Cited by 8
Begg, A. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-444-53632-7.00803-0 · Cited by 7
Pham, A. T., Yuan, F., Nagathihalli, N. S., & Dosch, A. R. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101309 · Cited by 5
DNA Double-Strand Break Repair by Non-homologous End Joining and Its Clinical Relevance
Weinfeld, M., & Lees‐Miller, S. P. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-384999-1.10008-3 · Cited by 5
Self-citationResistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations
Dhillon, K. K., & Taniguchi, T. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-14151-0_18 · Cited by 5
Mini, E., Landini, I., Lucarini, L., Lapucci, A., Napoli, C., Perrone, G., Tassi, R., Masini, E., Moroni, F., & Nobili, S. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x14926854178616 · Cited by 5
Poly (ADP-Ribose) Polymerase 1 and 2 in B-Cell Lymphoma
Molina‐Alvarez, A., Sánchez‐González, B., Colomo, L., & Yélamos, J. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.07.004 · Cited by 4
Predicting PARP inhibitor sensitivity and resistance
Bebb, D. G., & Lees‐Miller, S. P. (2012) · Cell Cycle · doi:10.4161/cc.22604 · Cited by 4
Self-citationZhou, J., Sturtevant, D., Love, C., Kulkarni, A., Biyani, N., Kathad, U., Thacker, E., Davé, S. S., & Bhatia, K. G. (2023) · Oncotarget · doi:10.18632/oncotarget.28454 · Cited by 4
Inhibition of DNA Repair as a Therapeutic Target
Veuger, S. J., & Curtin, N. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00008-5 · Cited by 4
Malenge, M. M., Maaland, A. F., Repetto‐Llamazares, A. H. V., Middleton, B. J., Nijland, M., Visser, L., Patzke, S., Heyerdahl, H., Kolstad, A., Stokke, T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267543 · Cited by 3
Maëda, J., Haskins, J. S., & Kato, T. A. (2023) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2023.111815 · Cited by 3
Development of Poly(ADP-Ribose)Polymerase (PARP) Inhibitors in Oncology
JONES, P. G. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45014-9 · Cited by 3
KRAS-Wild Pancreatic Cancer—More Targets than Treatment Possibilities?
Krupa, K., Fudalej, M. M., Miski, H., Włoszek, E., Szymczak, M., Badowska-Kozakiewicz, A. M., Czerw, A. I., & Deptała, A. (2025) · Cancers · doi:10.3390/cancers17233769 · Cited by 2
Targeting DNA Repair Pathways for Cancer Therapy
Vens, C., & Sobol, R. W. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_6 · Cited by 2
Shi, C., Ren, D., Gao, Y., Dang, Y., Tu, Z., & Liu, H. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.01.006 · Cited by 2
Biard, D. S. F. (2011) · InTech eBooks · doi:10.5772/23681 · Cited by 3
Lee, S., & Oh, S. C. (2016) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2016.03.12 · Cited by 2
Lokhande, L., Emruli, V. K., Eskelund, C. W., Kolstad, A., Hutchings, M., Räty, R., Niemann, C. U., Grønbæk, K., Jerkeman, M., & Ek, S. (2021) · Cancer Reports · doi:10.1002/cnr2.1524 · Cited by 2
Synthetic Lethality with Homologous Recombination Repair Defects
Bryant, H. E., & Shall, S. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-14151-0_13 · Cited by 1
Santos, E. S. D., Cicilini, A. L., Simões, M. F. E., Baz, M., Caputo, S. M., & Rouleau, É. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156754 · Cited by 2
Kukreja, R. C. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001591 · Cited by 1
PARP inhibition tested in a mammary epithelial cell line model
Halldorsdottir, A. M. (2010)
Novel Therapeutic Targets in Soft Tissue Sarcomas
Quincy, S. C., & Karen, E. P. (2011) · InTech eBooks · doi:10.5772/27522
Synthetic lethality in NSCLC cells: Interrogating the therapeutic potential of ATM deficiency
Elegbede, A. A. (2014) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/27960
Sousa, F. G. (2012) · Americanae (AECID Library)
Daemen, A., Wolf, D. M., Jakkula, L. R., Wang, N. J., Spellman, P. T., Frankum, J. R., Brough, R., Natrajan, R., Reis-Filho, J. S., Lord, C. J., et al. (2012)
Saravani, R., Sargazi, S., Galavi, H., & Zarei, S. (2017) · Gene Cell and Tissue · doi:10.5812/gct.62160
Pre-clinical Profile and Expectations for Pharmacological ATM Inhibition
Weber, A. M., & Ryan, A. J. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-75836-7_7
Marcos, I. C. (2019) · Gredos (University of Salamanca) · doi:10.14201/gredos.140375
Barlési, F., Tomasini, P., Karimi, M., Michiels, S., Raimbourg, J., Daniel, C., Janicot, H., Madroszyk, A., Audigier-Valette, C., Quoix, É., et al. (2023) · doi:10.1158/1078-0432.22487619.v1
Barlési, F., Tomasini, P., Karimi, M., Michiels, S., Raimbourg, J., Daniel, C., Janicot, H., Madroszyk, A., Audigier-Valette, C., Quoix, É., et al. (2023) · doi:10.1158/1078-0432.22487619
Zimmermann, A., Zenke, F. T., Chiu, L.-Y., Dahmen, H., Pehl, U., Fuchß, T., Grombacher, T., Blume, B., Vassilev, L. T., & Blaukat, A. (2023) · doi:10.1158/1535-7163.c.6543315
Zimmermann, A., Zenke, F. T., Chiu, L.-Y., Dahmen, H., Pehl, U., Fuchß, T., Grombacher, T., Blume, B., Vassilev, L. T., & Blaukat, A. (2023) · doi:10.1158/1535-7163.c.6543315.v1
Zimmermann, A., Zenke, F. T., Chiu, L.-Y., Dahmen, H., Pehl, U., Fuchß, T., Grombacher, T., Blume, B., Vassilev, L. T., & Blaukat, A. (2023) · doi:10.1158/1535-7163.22522257
Zimmermann, A., Zenke, F. T., Chiu, L.-Y., Dahmen, H., Pehl, U., Fuchß, T., Grombacher, T., Blume, B., Vassilev, L. T., & Blaukat, A. (2023) · doi:10.1158/1535-7163.22522278
Zimmermann, A., Zenke, F. T., Chiu, L.-Y., Dahmen, H., Pehl, U., Fuchß, T., Grombacher, T., Blume, B., Vassilev, L. T., & Blaukat, A. (2023) · doi:10.1158/1535-7163.22522278.v1
Barlési, F., Tomasini, P., Karimi, M., Michiels, S., Raimbourg, J., Daniel, C., Janicot, H., Madroszyk, A., Audigier-Valette, C., Quoix, É., et al. (2023) · doi:10.1158/1078-0432.22700533.v1
Overcoming resistance in prostate cancer with targeted and small molecule-based therapies
Gogola, S., Rejzer, M., & Poppiti, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16032-5.00008-7
Jiang, Z., Xu, B., Sun, B. H., Yang, B., Lu, S., Li, M., Zhang, J., Qi, L., & Wu, Q. (2025) · Future Science OA · doi:10.1080/20565623.2025.2458432
Repurposing of PARP Inhibitors for the Clinical Management of Acute Cardiotoxicity
Gallyas, F., Halmosi, R., & Toth, K. (2025) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-90598-8_37
Metadata
- Authors
- Williamson, C. T., Muzik, H., Turhan, A. G., Zamò, A., O'Connor, M. J., Bebb, D. G., & Lees-Miller, S. P.
- Affiliations
- University of Verona (IT)
- Authors' Affiliations: Departments of 1Biochemistry and Molecular Biology and 2Oncology and 3Southern Alberta Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada; 4Inserm U935, University of Poitiers and Service d'Hématologie et d'Oncologie Biologique EA 3805, CHU de Poitiers, Poitiers, France; 5Dipartimento di Patologia, Sezione di Anatomia Patologica, University of Verona, Verona, Italy; and 6KuDOS Pharmaceuticals, Cambridge, United Kingdom
- Corresponding author
- Bebb, D. Gwyn
- Venue
- Molecular Cancer Therapeutics
- Published
- 2010-02-01
- Volume
- 9
- Issue
- 2
- Pages
- 347-357
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- PMC
- PMC3729269
- OpenAlex
- W2103272465
- Cited by
- 193
- References
- 54
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 16 · 2022: 4 · 2021: 6 · 2020: 13 · 2019: 12 · 2018: 12 · 2017: 12 · 2016: 13 · 2015: 17 · 2014: 12 · 2013: 20 · 2012: 20
- FWCI
- 9.95
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Cancer Institute (P01-CA 92584, P01CA092584)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- mantle cell lymphoma, ATM deficiency, PARP-1 inhibitors, olaparib, synthetic lethality, DNA repair deficiency, radiosensitivity, xenograft tumor growth, overall survival
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Animals, DNA Repair, DNA-Binding Proteins, Female, Humans, Neoplasm Transplantation, Phosphorylation, Phthalazines, Piperazines, Radiation, Ionizing, Trypan Blue, Annexin A5, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Lymphoma, Mantle-Cell, Tumor Suppressor Proteins, Cell Line, Tumor, Mice, Ataxia Telangiectasia Mutated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
